T1	Participants 85 103	multiple sclerosis
T2	Participants 185 217	patients with multiple sclerosis
T3	Participants 802 849	eight patients with definite multiple sclerosis
T4	Participants 1231 1293	Three out of eight patients dropped out due to adverse effects
T5	Participants 1406 1459	Three patients decided to continue gabapentin therapy
